Company Press Release
Cruttenden Roth Recommends Buy of Cypros Pharmaceutical
IRVINE, Calif.--(BUSINESS WIRE)--July 28, 1997--On July 16, 1997, William R. Prather R. Ph, M.D., a research
analyst for Cruttenden Roth, initiated coverage of Cypros Pharmaceutical Corp. (NASDAQ:CYPR) with a ``buy'' rating and
a twelve month price target of $10.50 per share.
In his 26-page report, Dr. Prather cited the following as one of his reasons for the recommendation: ``Independent clinical
data on Cypros Pharmaceutical's lead product, naturally occurring CPC-111, leads us to the conclusion that this compound
could become the standard of care in the potential multi-billion dollar cardioprotection market.''
Cypros Pharmaceutical is engaged in the development and marketing of drug products for the hospital market. The company
is pursuing a diversified strategy of marketing approved drugs and developing small molecule therapeutics that protect cells
from ischemic injury. The company currently has three products on the market, Glofil, Inulin and Ethamolin(R). The
company's CPC-111 and CPC-211 drugs are currently in Phase II clinical trials for a variety of cardiovascular and
neurological disorders. |
